BioSpace News Archive

First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of WVE-004 dosing

Arbor Biotechnologies, an early-stage life sciences company discovering and developing the next generation of genetic medicines, announced the appointments of Pam Stetkiewicz, Ph.D., as Chief Operating Officer, and Kathryn McCabe, Ph.D., as SVP, Head of Business Development.

Kineta to leverage Samsung Biologics’ development and manufacturing expertise to advance KVA12.1 to IND Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service.

Micronoma, the first cancer detection company to harness tumor-associated circulating microbial biomarkers to diagnose cancer at an early stage via microbiome-driven liquid biopsy technology, announced a collaboration with the University of New South Wales, Sydney for a $4 million grant from the Australian Government to fund research into hepatocellular carcinoma, the most common type of primary liver cancer.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitreoretinal lymphoma (PVRL).

Neuronetics, Inc. today announced that it plans to release second quarter financial and operating results prior to market open on Tuesday, August 3, 2021.

Varex Imaging Corporation (Nasdaq: VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2021 following the close of regular trading on Tuesday, August 3, 2021.

Phase 1b study data demonstrate non-invasive white matter imaging enables better drug targeting in specific areas of the brain

Through a collaborative effort, spearheaded by professors, Dr. Vladimir Yarov-Yarovoy and Dr. Heike Wulff at UC Davis and supported in part by an NIH initiative, researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

Neuropathix, Inc., a socially responsible pain management life sciences company, announced the publication of the global Patent Cooperation Treaty Patent under Publication No. WO/2021/097351.